Anavex Life Sciences's gross profit for the
three
months ended in Mar. 2024 was €0.00 Mil. Anavex Life Sciences's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was €0.00 Mil.
Anavex Life Sciences had a gross margin of N/A% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage
Anavex Life Sciences Gross Profit Historical Data
The historical data trend for Anavex Life Sciences's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Anavex Life Sciences's Gross Profit
For the Biotechnology subindustry, Anavex Life Sciences's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anavex Life Sciences's Gross Profit Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Anavex Life Sciences's Gross Profit distribution charts can be found below:
* The bar in red indicates where Anavex Life Sciences's Gross Profit falls into.
Anavex Life Sciences Gross Profit Calculation
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
Anavex Life Sciences's Gross Profit for the fiscal year that ended in Sep. 2023 is calculated as
Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
(Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Anavex Life Sciences (STU:12X1) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Anavex Life Sciences had a gross margin of N/A% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage
Anavex Life Sciences Gross Profit Related Terms
Thank you for viewing the detailed overview of Anavex Life Sciences's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
Anavex Life Sciences (STU:12X1) Business Description
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
STU:12X1 has been successfully added to your 